Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
Related Posts
Debonnaire P, Zwetsloot PP, Pfister R, Llàcer P, Cipriani A, Milani P, Bonderman D, Ohlmeier C, Evers T, Wyss R, Patorno E, Doshi R, Beisel[...]
Vershel C, Kim S, Gensler LS, Brown MA, Weisman MH, Ishimori ML, Ward M, Reveille JD, Hwang MC. Examining the Interchangeability of Two Different Patient-Reported[...]
Rutkovskis E, Ravagli E, Lancashire HT, Shah Idil A, Thompson N, Perkins JD, Challita R, Hadaya J, Vivekananda U, Ajijola O, Shivkumar K, Miserocchi A,[...]